Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NZV930
i
Other names:
NZV930, SRF373
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Coherus Biosci
Drug class:
CD73 inhibitor
Related drugs:
‹
MEDI9447 (6)
TJD5 (3)
INT-1B3 (1)
ABSK051 (0)
BMS-986179 (0)
BP1200 (0)
HB0045 (0)
HLX23 (0)
INCA00186 (0)
IPH5301 (0)
ORIC-533 (0)
PM1015 (0)
S95024 (0)
AGEN1423 (0)
AK119 (0)
CPI-006 (0)
AB680 (0)
MEDI9447 (6)
TJD5 (3)
INT-1B3 (1)
ABSK051 (0)
BMS-986179 (0)
BP1200 (0)
HB0045 (0)
HLX23 (0)
INCA00186 (0)
IPH5301 (0)
ORIC-533 (0)
PM1015 (0)
S95024 (0)
AGEN1423 (0)
AK119 (0)
CPI-006 (0)
AB680 (0)
›
Associations
News
Trials
Filter by
Latest
1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business reasons
1 year ago
Trial termination • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=77, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=145 --> 77
1 year ago
Enrollment closed • Enrollment change • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
over1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=145, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2025 --> Sep 2023 | Trial primary completion date: Feb 2025 --> Sep 2023
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
over1year
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=145, Recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
over 1 year ago
Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
spartalizumab (PDR001) • KAZ954 • NZV930 • taminadenant (NIR178)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login